Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis

Acta Oncologica

Volumn 46, Issue 5, 2007, Pages 664-668

  Ortega, Cinzia ^a   Montemurro, Filippo ^a   Faggiuolo, Roberto ^a   Vormola, Roberto ^a   Nanni, Daniela ^a   Goia, Franco ^b   Gilardino, Marco Ottavio ^b   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN DERIVATIVE; MITOMYCIN C; ZOLEDRONIC ACID;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; JAW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; PROSTATIC NEOPLASMS;

EID: 34250370376     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860601185917     Document Type: Article

References (25)

1. Green JR. Skeletal complications of prostate cancer: Pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol 2005;44:282-92.
2. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol 2006;24:4-12.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
4. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone. Cancer 2005;104:83-93.
5. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
6. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
7. Sanna G, Zampino MG, Pelosi G, Nole F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol 2005;16:1207-8.
8. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-7.
9. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8.
10. Balcewicz-Sablinska MK, Gonzáles-Pérez A, Garcia Rodríguez LA. Risk of osteonecrosis in cancer patients. Ann Epidemiol 2004;14:593 (P006).
11. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
12. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
13. Ortega C, Faggiuolo R, Vormola R, Montemurro F, Nanni D, Goia F, et al. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 2006;45:216-7.
14. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57.
15. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
16. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
17. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
18. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
19. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
20. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;6:15.
21. Tarassoff P, Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9.
22. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005;96:964-9.
23. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
24. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
25. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-95.